🔗 Share this article World Health Organization Sounds Alert Over Severe Shortage of Weight-Loss Injections Less than a tenth of patients that would benefit from obesity jabs like Wegovy have access to them, states the World Health Organization as it issues its initial recommendations on the therapies. Considering over a billion individuals worldwide currently obese, it is advocating for increased and just access to these injectable treatments. Per estimates, over two billion will be living with obesity by 2030 unless action is taken. "Our latest guidelines recognises that excess weight is a lifelong illness that can be managed with thorough and lifelong treatment," remarked its chief Tedros Adhanom Ghebreyesus. High costs, constrained manufacturing, and supply-chain constraints are major barriers to widespread availability to the injections that can aid individuals in losing considerable weight, notes the agency. GLP-1 Therapy Scarcity Even in the current most favorable case, the manufacturing of GLP-1 therapies could only cover approximately 100 million people – under 10% of the global need, per the WHO. The advice calls on nations and manufacturers to increase access, by strategies including voluntary licensing. The intellectual property rights on the active ingredient – the main component of the drug Wegovy – is set to lapse in several countries in 2026. How Obesity Jabs Operate These medications replicate a body's own hormone to reduce digestion speed, suppress the appetite and increase satiety so users reduce food intake. Individuals typically begin shedding pounds in the initial weeks of commencing the once-weekly jabs. Research suggests users may see weight return within a year of stopping the medication, because their usual food cravings come back. To be carrying excess weight increases your chance for experiencing medical conditions, such as type 2 diabetes, heart disease, brain attack, and some malignancies. Excess weight affects people in countries worldwide and was responsible for 3.7 million deaths worldwide in 2024, as per the health agency.
Less than a tenth of patients that would benefit from obesity jabs like Wegovy have access to them, states the World Health Organization as it issues its initial recommendations on the therapies. Considering over a billion individuals worldwide currently obese, it is advocating for increased and just access to these injectable treatments. Per estimates, over two billion will be living with obesity by 2030 unless action is taken. "Our latest guidelines recognises that excess weight is a lifelong illness that can be managed with thorough and lifelong treatment," remarked its chief Tedros Adhanom Ghebreyesus. High costs, constrained manufacturing, and supply-chain constraints are major barriers to widespread availability to the injections that can aid individuals in losing considerable weight, notes the agency. GLP-1 Therapy Scarcity Even in the current most favorable case, the manufacturing of GLP-1 therapies could only cover approximately 100 million people – under 10% of the global need, per the WHO. The advice calls on nations and manufacturers to increase access, by strategies including voluntary licensing. The intellectual property rights on the active ingredient – the main component of the drug Wegovy – is set to lapse in several countries in 2026. How Obesity Jabs Operate These medications replicate a body's own hormone to reduce digestion speed, suppress the appetite and increase satiety so users reduce food intake. Individuals typically begin shedding pounds in the initial weeks of commencing the once-weekly jabs. Research suggests users may see weight return within a year of stopping the medication, because their usual food cravings come back. To be carrying excess weight increases your chance for experiencing medical conditions, such as type 2 diabetes, heart disease, brain attack, and some malignancies. Excess weight affects people in countries worldwide and was responsible for 3.7 million deaths worldwide in 2024, as per the health agency.